Project Grant R35GM153401
- The National Science Foundation (NSF) Division of Molecular and Cellular Biosciences awarded a $590,000 Project Grant to the University of California Irvine (UC Irvine) on August 15, 2023 under the Biological Sciences program (CFDA 47.074). The goal of this 3-year research project is to develop novel strategies for real-time metabolite sensing and metabolite-induced enzyme localization that can contribute to fundamental cellular knowledge and improve the efficiency of synthetic biology...
- The National Science Foundation (NSF) Division of Molecular and Cellular Biosciences and the Division of Chemical, Bioengineering, Environmental and Transport Systems awarded a $240,000 Project Grant to the University of California Irvine (UC Irvine) under the NSF Biological Sciences program (CFDA 47.074). The grant supports collaborative research to develop unnatural cofactors that can be deployed as stronger-than-nature thermodynamic driving forces in biomanufacturing processes. This is...
- The National Institute of General Medical Sciences (NIGMS) awarded a $216,906 Project Grant to The Regents of the University of Colorado, doing business as the University of Colorado Office of Contracts and Grants Division, to conduct research on the "Evolution of Novel Metabolic Pathways" under CFDA Program 93.859 - Biomedical Research and Research Training. The funding will support the University's efforts to study how organisms can evolve new metabolic pathways to access new...
- This Project Grant award from the National Science Foundation (NSF) under the Biological Sciences program (CFDA 47.074) provides $369,297 to San Francisco State University (SFSU) to develop a synthetic transhydrogenation module to enhance the production of valuable chemicals using engineered organisms. The key objectives are to: Elucidate the structural mechanisms underlying the autoregulation of the GltAB-GudB enzyme complex in Bacillus subtilis, which regulates glutamate metabolism and impacts...
- This Project Grant award of $249,000.00 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) is to support research at Duke University to expand the capabilities of enzymes beyond their natural functions for synthesizing medicinally important chemical compounds. The key products or services to be delivered include engineering heme enzymes and methionine sulfoxide reductases to catalyze aminations and oxidations,...
- This Project Grant award from the National Science Foundation's Engineering program (CFDA 47.041) provides $575,765 to Northeastern University to conduct research focused on "metabolic 'doping' to enhance production of biochemicals from sustainable C1 feedstocks." The key objectives are to understand the regulation of carbon metabolism in acetogens, bacteria that can grow on single-carbon (C1) molecules, and to genetically engineer these organisms to become more effective producers...
- The National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), awarded a $385,298 project grant to The Research Foundation for The State University of New York (Stony Brook University) for the period of February 1, 2025 to December 31, 2029. The project aims to develop a new biomimetic organic synthesis approach that leverages rationally designed pyridoxal-5'-phosphate (PLP)-mimicking catalysts to enable open-shell radical...
- The National Science Foundation (NSF) Division of Molecular and Cellular Biosciences awarded a $750,000 Project Grant to The Washington University in St. Louis to support research and training related to understanding how metabolic burdens affect microbial cells used in biotechnology applications. The 3-year award, which commenced on August 15, 2023, will enable the Principal Investigator to acquire expertise in modern metabolomics and gene editing techniques, and apply these methods to...
- This federal Project Grant award of $386,617 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) aims to develop safer and more efficient chemical methods for the synthesis of complex, fluorinated, and highly functional pharmaceutical compounds. The key research areas encompass: (1) electromicellar catalysis for the formation of fluorinated heterocycles, allenes, and reactive intermediates; (2) enantioselective...
- This Project Grant award from the National Science Foundation's (NSF) Mathematical and Physical Sciences program (CFDA 47.049) to the University of California, Berkeley provides $780,000 in funding to investigate the molecular mechanisms of oxygen-dependent enzymes and develop synthetic mimics. The key objectives are to study a class of oxygen-dependent decarboxylase enzymes that utilize iron, manganese, or mixed metal active sites. This research aims to elucidate the critical oxygen-activated...
EXPANDING THE METABOLIC CURRENCIES OF LIFE - THERE IS AN UNMET NEED TO OBTAIN NATURAL PRODUCT-DERIVED MEDICINES IN A SCALABLE AND RELIABLE MANNER. NATURAL PRODUCTS ARE SMALL MOLECULES PRODUCED BY BIOLOGICAL SYSTEMS, BUT OFTEN IN LOW QUANTITIES. SYNTHETIC BIOLOGY PROMISES TO MOVE THE BIOSYNTHETIC PATHWAYS OF THESE MEDICINAL SMALL MOLECULES FROM THEIR NATIVE PRODUCERS INTO HETEROLOGOUS HOSTS SUCH AS BACTERIA AND YEAST OR INTO A BIOREACTOR, SO THAT LARGE-SCALE, LOW-COST, INDUSTRIAL PROCESSES CAN BE DEVELOPED TO PRODUCE THEM. THE LONG-TERM GOAL OF MY RESEARCH PROGRAM IS TO ADDRESS THE ULTIMATE CHALLENGE IN CHEMICAL BIOSYNTHESIS, NAMELY TO PRECISELY CONTROL THE FLOW OF ELECTRONS, CARBON, AND ENERGY. OVER THE PAST FIVE YEARS, WE HAVE MADE SUBSTANTIAL STRIDES TOWARD THIS GOAL, BY ESTABLISHING UNNATURAL ELECTRON CURRENCY WHICH OPERATES IN PARALLEL TO NATURE'S UNIVERSAL COFACTOR. THIS DESIGN IS INSPIRED BY NATURE: CATABOLISM AND ANABOLISM, TWO OPPOSING METABOLIC SYSTEMS RESPONSIBLE FOR BREAKING DOWN AND BUILDING UP CELL COMPONENTS, RESPECTIVELY, ARE INSULATED FROM EACH OTHER BECAUSE THEY EACH HAVE A DESIGNATED REDOX COFACTOR, NAD AND NADP, RESPECTIVELY. WE HAVE DEMONSTRATED THAT OUR UNNATURAL COFACTOR CAN INDEED PRECISELY CHANNEL REDUCING POWER ONLY TO THE DESIRED PHARMACEUTICAL PRODUCING REACTIONS INSIDE THE CELLS WHILE SILENCING ALL SIDE-REACTIONS, EFFECTIVELY INSULTING THE BIOSYNTHETIC PATHWAY FROM THE HOST'S COMPLEX NATIVE METABOLISM. IMPORTANTLY, WE HAVE ALSO DEVELOPED UNIVERSAL, HIGH-THROUGHPUT, GROWTH-BASED SELECTION PLATFORMS TO READILY OBTAIN ENZYMES THAT CAN USE THE UNNATURAL COFACTOR. THROUGH THESE EFFORTS, GENERAL ENZYME DESIGN PRINCIPLES ALSO START TO EMERGE WHICH PAVES THE WAY FOR OUR PROPOSED WORK IN THE NEXT FIVE YEAR. THROUGH THE MIRA SUPPORT, WE WILL DEVELOP METHODS TO DRASTICALLY IMPROVE THE EFFICIENCY OF THE UNNATURAL COFACTOR TECHNOLOGY; MAKE IT EASY TO ADOPT BY BIOENGINEERING COMMUNITY; BRING THIS TECHNOLOGY TO BEAR ON DIFFICULT HIGH-REWARD BIOSYNTHESIS CHALLENGES; BROADEN THE CATEGORY OF UNNATURAL METABOLIC CURRENCIES FROM ELECTRON- TO CARBON- AND ENERGY-CARRIERS AND DISTILL TRANSLATABLE DESIGN PRINCIPLES; USE THIS PROJECT AS A VEHICLE TO INCLUDE AND PROMOTE DIVERSE STEM RESEARCHERS AT K-12, UNDERGRADUATE, GRADUATE, AND POST GRADUATE STAGES. THE PROPOSED WORK IS TRANSFORMATIVE BECAUSE IT DIRECTLY TARGETS LIFE'S UNIVERSAL METABOLIC INFRASTRUCTURE AND THEREFORE CAN HAVE EXTREMELY BROAD IMPACTS IN BIOMEDICINE AND SYNTHETIC BIOLOGY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $413.5k | 4/7/25 | ||
| Not listed | $0 | 11/21/24 | ||
| Not listed | $0 | 11/21/24 | ||
| Not listed | $555.9k | 5/17/24 | ||
| Not listed | $555.9k | 5/17/24 |